Osteosarcoma: Basic Science and Clinical Implications

Hayden, James B.; Hoang, Bang H.

doi:10.1016/j.ocl.2005.06.004

Cited by 109 publications

(97 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…these patients could potentially be treated differently. the second area of focus has been to identify new targets for therapy that may be more effective or less toxic, especially for the tumors that respond poorly to the conventional agents (4).…”

Section: Introductionmentioning

confidence: 99%

The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells

Zheng

Xu²,

Peng³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. pharmacological inhibition of DnA repair pathways has been emerging as an effective tool for cancer treatment. poly(ADp-ribose) polymerase (pArp) is involved in DnA repair and transcriptional regulation and is now recognized as a key regulator of cell survival and cell death. In vitro and in vivo data suggest that pArp inhibitors could be used not only as chemo/radiotherapy sensitizers but also as single agents to selectively kill cancer cells in certain types of tumors. In the present study, we investigate the effects of 3-aminobenzamide (3-AB), a potent inhibitor of pArp, on human osteosarcoma cells and whether or not it can sensitize the tumor cells to chemotherapeutic agents. the results indicated that 3-AB suppressed U2os cell growth in a time-and dose-dependent manner, and the suppressive effects of 3-AB were associated with increased cell apoptosis. In addition, 3-AB suppressed cell invasion in vitro and enhanced the suppressive effects of cisplatin in U2os cells. our work suggests that this pArp-1 inhibitor may be developed into an effective agent for the treatment of human osteosarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells

Zheng

Xu²,

Peng³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Osteosarcoma, the most common bone sarcoma, predominantly affects rapidly growing bones in adolescents [25]. Although only approximately 400 cases occur in the United States per year, osteosarcoma is the fifth most frequent malignancy in 15 to 19 year olds [63].…”

Section: Introductionmentioning

confidence: 99%

“…Although only approximately 400 cases occur in the United States per year, osteosarcoma is the fifth most frequent malignancy in 15 to 19 year olds [63]. Before the development of chemotherapy regimens, long-term survival rates were 10% to 20% with surgical resection, usually amputation, as the only treatment available [25,39,63]. During the 1970s, initiation of chemotherapy protocols in combination with aggressive surgical resection resulted in long-term survival rates of 60% to 70% in patients with localized disease [7,38,39].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Specific Tyrosine Kinase Inhibitors Regulate Human Osteosarcoma Cells In vitro

Messerschmitt

Rettew

Brookover

et al. 2008

Clin Orthop Relat Res

View full text Add to dashboard Cite

Inhibitors of specific tyrosine kinases are attractive lead compounds for development of targeted chemotherapies for many tumors, including osteosarcoma. We asked whether inhibition of specific tyrosine kinases would decrease the motility, colony formation, and/or invasiveness by human osteosarcoma cell lines (TE85, MNNG, 143B, SAOS-2, LM-7). An EGF-R inhibitor reduced motility of all five cell lines by 50% to 80%. In contrast, an IGF-1R inhibitor preferentially reduced motility by 42% in LM-7 cells and a met inhibitor preferentially reduced motility by 80% in MNNG cells. The inhibitors of EGF-R, IGF-1R, and met reduced colony formation by more than 80% in all tested cell lines (TE85, MNNG, 143B). The EGF-R inhibitor reduced invasiveness by 62% in 143B cells. The JAK inhibitor increased motility of SAOS-2 and LM7 cells without affecting colony formation or invasiveness. Inhibitors of HER-2, NGF-R, and PDGF-Rs did not affect motility, invasiveness, or colony formation. These results support the hypothesis that specific tyrosine kinases regulate tumorigenesis and/or metastasis in osteosarcoma.

show abstract

“…Osteosarcoma has an overwhelming tendency for invasion and early metastasis (2). Although treatment with surgery and neoadjuvant chemotherapy appears to cure 60-70% of cases (3), the 5-year survival rate for patients with recurrent and metastatic osteosarcoma is only 20% (4,5).…”

Section: Introductionmentioning

confidence: 99%

Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma

et al. 2016

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most prevalent type of primary malignant bone tumor. Inhibitor of growth 4 (ING4) has been demonstrated to function as a tumor suppressor through multiple pathways, and is its expression is understood to be suppressed or reduced in various malignancies. The present study aimed to investigate the expression of ING4 and to determine its prognostic value in osteosarcoma tissue. Formalin-fixed, paraffin-embedded tissue microarrays were analyzed, and contained 41 osteosarcoma specimens and 11 normal bone tissue specimens with duplicate cores. ING4 expression was evaluated by immunohistochemical staining. The association between ING4 expression in the osteosarcoma and normal bone tissues was analyzed, in addition to the association between ING4 expression and Enneking classification of the osteosarcoma tissues. A significant statistical difference was observed in the ING4 immunohistochemical staining score between the osteosarcoma and normal bone tissues (P<0.001). Furthermore, a significant negative correlation was detected between the ING4 immunohistochemical staining scores and the Enneking classification results of the 41 osteosarcoma tissues (P=0.002). Low expression of ING4 was observed in the osteosarcoma specimens, and this reduced expression of ING4 was negatively correlated with Enneking classification. Thus, the results of the present study indicate that ING4 may serve as a promising prognostic marker in osteosarcoma. IntroductionOsteosarcoma, the most common primary bone malignancy, accounts for ~20% of all bone tumors and ~5% of all pediatric tumors (1). Osteosarcoma has an overwhelming tendency for invasion and early metastasis (2). Although treatment with surgery and neoadjuvant chemotherapy appears to cure 60-70% of cases (3), the 5-year survival rate for patients with recurrent and metastatic osteosarcoma is only 20% (4,5). Research investigating the mechanism of osteosarcoma development has primarily focused on chromosomal abnormalities, genetic alterations of tumor suppressor genes, activation of oncogenes and dysregulation of major signaling pathways. However, the molecular events that lead to the development of osteosarcoma are not yet fully understood.Inhibitor of growth 4 (ING4) functions as a tumor suppressor, thus serving an inhibitory role during the generation and development of various types of tumor, including thyroid (6), gastric (7), lung (8) and breast cancer (9). ING4 physically interacts with and phosphorylates p65, a subunit of nuclear factor-κB (NF-κB), therefore suppressing the activity of NF-κB (10). The inhibition of NF-κB negatively regulates various target genes, including matrix metalloproteinase (MMP)-2, MMP-9, interleukin (IL)-6, IL-8, cyclooxygenase-2 and colony stimulating factor-3. The downregulation of these cytokines inhibits angiogenesis and tumor cell growth (11-15). In RKO colorectal cancer cells, ING4 expression was able to decrease the cell population in the S-phase of the cell cycle in a p53-dependent manner, as well as upregulate p21...

show abstract

Osteosarcoma: Basic Science and Clinical Implications

Cited by 109 publications

References 32 publications

The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells

The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells

Specific Tyrosine Kinase Inhibitors Regulate Human Osteosarcoma Cells In vitro

Reduced expression and prognostic implication of inhibitor of growth 4 in human osteosarcoma

Contact Info

Product

Resources

About